[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100601218",false,"NCT07107633","A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.","A Multicenter, Open-access, Self-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mTc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignancies.","Inclusion Criteria:\n\nOnly those who meet all the following requirements are eligible to join the group:\n\n1. Adults over 18 years of age (based on the time when the informed consent form was signed) can be male or female;\n2. Subjects with gastrointestinal malignant tumor confirmed by histology\u002Fcytology;\n3. Subjects to be surgically removed or explored;\n4. The estimated survival time is ≥12 weeks;\n5. Subjects of childbearing age agreed to adopt effective contraceptive measures during the study period;\n6. Subjects fully understand the purpose, nature, methods and possible adverse reactions of the experiment, voluntarily participate in and sign a written informed consent, and are willing to follow the requirements of the protocol to complete the study.riteria:\n\nThose who meet one of the following items are not allowed to join the group:\n\n1. According to the researcher's judgment, during the screening period, from the imaging examination to the comprehensive real diagnosis information result, the patients were treated with anti-digestive tract tumor;\n2. symptomatic brain metastases who need treatment;\n3. Have serious cardiovascular and cerebrovascular diseases;\n4. There are other contraindications for imaging examination of the research plan, such as claustrophobia;\n5. Have a history of other malignant tumors;\n6. Pregnant (pregnancy test positive in screening period) or lactating women;\n7. Other circumstances that the researcher considers inappropriate to participate in this clinical trial.","ALL","18 Years",{"count":18,"type":19},90,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","The main purpose of this study is to evaluate the effectiveness of technetium \\[99mTc\\]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor. Objective: To evaluate the safety of technetium \\[99mTc\\]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor. Objective: To explore the diagnostic threshold of technetium \\[99mTc\\]-H7ND injection for peritoneal metastasis of gastrointestinal malignant tumor.",[25,26],"Solid Tumor","Peritoneal Metastasis","RECRUITING","2025-08-04",{"date":30,"type":31},"2025-08-06","ACTUAL",{"date":33,"type":31},"2025-03-12",{"date":35,"type":19},"2025-09",{"name":37,"class":38},"Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.","OTHER",""]